SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

2/3/23 4:27:14 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TGTX alert in real time by email

SC 13G/A 1 TG_Therapeutics_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMEMDED FILING TG THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 88322Q108 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO: 88322Q108 13G PAGE 2 OF 7 PAGES 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 10,054,676 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 10,415,161 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,415,161 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.17% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 88322Q108 13G PAGE 3 OF 7 PAGES 1. NAME OF REPORTING PERSON: SSGA FUNDS MANAGEMENT, INC. I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-3555193 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 7,353,870 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 7,383,370 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,383,370 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.08% 12. TYPE OF REPORTING PERSON IA CUSIP NO: 88322Q108 13G PAGE 4 OF 7 PAGES ITEM 1. (A) NAME OF ISSUER TG THERAPEUTICS INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION SSGA FUNDS MANAGEMENT, INC. (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 LINCOLN STREET BOSTON, MA 02111 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 88322Q108 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO: 88322Q108 13G PAGE 5 OF 7 PAGES ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS NOT APPLICABLE ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO: 88322Q108 13G PAGE 6 OF 7 PAGES ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER SSGA FUNDS MANAGEMENT, INC. JACLYN COLLIER CHIEF COMPLIANCE OFFICER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION. CUSIP NO: 88322Q108 13G PAGE 7 OF 7 PAGES JOINT FILING AGREEMENT IN ACCORDANCE WITH RULE 13D-1(K)(1) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE EXCHANGE ACT), EACH UNDERSIGNED ENTITY (EACH A COMPANY) HEREBY AGREES TO ANY AND ALL JOINT FILINGS REQUIRED TO BE MADE ON THE COMPANY`S BEHALF ON SCHEDULE 13G (INCLUDING AMENDMENTS THERETO) UNDER THE EXCHANGE ACT, WITH RESPECT TO SECURITIES WHICH MAY BE DEEMED TO BE BENEFICIALLY OWNED BY THE COMPANY UNDER THE EXCHANGE ACT, AND THAT THIS AGREEMENT BE INCLUDED AS AN EXHIBIT TO ANY SUCH JOINT FILING. THIS AGREEMENT MAY BE EXECUTED IN ANY NUMBER OF COUNTERPARTS ALL OF WHICH TAKEN TOGETHER SHALL CONSTITUTE ONE AND THE SAME INSTRUMENT. IN WITNESS WHEREOF, EACH COMPANY HEREBY EXECUTES THIS AGREEMENT EFFECTIVE AS OF THE DATE SET FORTH BELOW. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER SSGA FUNDS MANAGEMENT, INC. JACLYN COLLIER CHIEF COMPLIANCE OFFICER

Get the next $TGTX alert in real time by email

Recent Analyst Ratings for

$TGTX

Date	Price Target	Rating	Analyst
10/6/2025	$60.00	Buy	H.C. Wainwright
7/10/2025	$37.00	Neutral	Goldman
10/29/2024	$50.00	Buy	TD Cowen
8/2/2023	$16.00 → $12.00	Sell → Neutral	Goldman
6/26/2023	$55.00 → $40.00	Buy	Jefferies
5/20/2022	$5.00	Underperform	BofA Securities
2/23/2022	$49.00 → $35.00	Buy	B. Riley Securities
1/28/2022	$70.00 → $68.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

2/3/23 4:27:14 PM ET

$TGTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TGTX alert in real time by email

Recent Analyst Ratings for

$TGTX

Date	Price Target	Rating	Analyst
10/6/2025	$60.00	Buy	H.C. Wainwright
7/10/2025	$37.00	Neutral	Goldman
10/29/2024	$50.00	Buy	TD Cowen
8/2/2023	$16.00 → $12.00	Sell → Neutral	Goldman
6/26/2023	$55.00 → $40.00	Buy	Jefferies
5/20/2022	$5.00	Underperform	BofA Securities
2/23/2022	$49.00 → $35.00	Buy	B. Riley Securities
1/28/2022	$70.00 → $68.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$TGTX

SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$TGTX

$TGTX
Press Releases

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

$TGTX
SEC Filings

TG Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by TG Therapeutics Inc.

SEC Form 10-Q filed by TG Therapeutics Inc.

$TGTX
Analyst Ratings

H.C. Wainwright resumed coverage on TG Therapeutics with a new price target

Goldman resumed coverage on TG Therapeutics with a new price target

TD Cowen initiated coverage on TG Therapeutics with a new price target

$TGTX
Insider Trading

CEO Weiss Michael S was granted 622,000 shares, increasing direct ownership by 7% to 9,778,086 units (SEC Form 4)

CFO Power Sean A was granted 90,000 shares, increasing direct ownership by 13% to 798,111 units (SEC Form 4)

Director Echelard Yann sold $162,850 worth of shares (5,000 units at $32.57), decreasing direct ownership by 2% to 223,816 units (SEC Form 4)

$TGTX
FDA approvals

FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

FDA Approval for UKONIQ

$TGTX
Financials

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

$TGTX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.